ICAHN School of Medicine At Mount Sinai

Simcere Zaiming has dosed the first US patient in a Phase 1 trial of SIM0500, a trispecific antibody targeting GPRC5D, BCMA, and CD3 for relapsed/refractory multiple myeloma treatment.

Penumbra has completed enrollment of 100 patients in the pivotal STORM-PE randomized controlled trial, comparing computer assisted vacuum thrombectomy plus anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism.

Alys Pharmaceuticals has submitted a Clinical Trial Application to Germany's Paul-Ehrlich-Institut for ALY-301, a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity.

Combination therapy of oral ritlecitinib plus narrowband UV-B phototherapy demonstrated superior repigmentation results compared to ritlecitinib monotherapy in nonsegmental vitiligo patients.

CoreMap has received FDA Investigational Device Exemption approval to extend its INvENI clinical study to the U.S., evaluating its proprietary electrophysiology mapping system in persistent atrial fibrillation patients.

Researchers at Mount Sinai have demonstrated that their personalized cancer vaccine PGV001, when combined with immune checkpoint inhibitor atezolizumab, is safe and generates strong immune responses in bladder cancer patients.

Novaremed AG has completed enrollment of 127 patients in an NIH-sponsored Phase 2b trial evaluating NRD.E1, a non-opioid investigational drug for chronic pain associated with diabetic peripheral neuropathy.

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

Archetype Therapeutics will present in vivo proof-of-concept data for AI-identified small molecules targeting early-stage lung adenocarcinoma at the 2025 AACR Annual Meeting.

Recent research published in JAMA predicts millions of preventable disease cases over the next 25 years if childhood vaccination rates continue to decline from their current level of under 93%.